Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Key facts
- Who runs it
- Medical University of Vienna
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 40 people enrolled
- Started
- 8 Oct 2024
- Expected to end
- Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- OMNi-BiOTiC® METAtox
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Pregnant women aged 18 to 50 years
- Gestational age 12+0 to 15+6 at inclusion
- Preconceptional body mass index ≥25 kg/m2
- Written informed consent
Who cannot take part
- Any acute illness within 2 weeks prior to the study
- Status post bariatric surgery
- Preconceptional diabetes (type 1, type 2 or others)
- Preconceptional endocrine disorder (Cushing Syndrome, M. Addison)
- HIV or hepatitis infection
- Current malignant tumors
- Severe liver or kidney dysfunction
- Participation in another interventional study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if taking a probiotic supplement during pregnancy improves the body's response to insulin (insulin sensitivity) in pregnant women who were overweight or obese before pregnancy (body mass index ≥25 kg/m2). Reduced insulin sensitivity is common in these women and increases the risk of gestational diabetes mellitus and excessive fetal growth. Growing evidence suggests that the bacteria in the gut (gut microbiome) play a role in regulating blood sugar and insulin action.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does a daily probiotic supplement improve insulin sensitivity in mid-pregnancy? * Does it affect blood sugar levels, insulin production, the development of gestational diabetes mellitus, fetal growth and the gut bacteria of mothers and newborns?
Participants will:
* Take one sachet of the probiotic OMNi-BiOTiC® METAtox twice daily from early pregnancy until delivery (probiotic group only) * Attend three study visits in early, mid and late pregnancy with blood tests, an oral glucose tolerance test (early and mid pregnancy), measurements of weight and blood pressure, and questionnaires on diet and physical activity * Wear a glucose sensor on the upper arm for 10 days after each visit * Provide stool samples at each visit and a first stool sample of their newborn * Have fetal growth checked by ultrasound and pregnancy and birth outcomes recorded
The 2 groups in the trial
- Probiotic supplementationTreatment being tested
Women with a preconceptional BMI ≥25 kg/m2 taking one sachet of OMNi-BiOTiC® METAtox twice a day starting from randomization (12+0 to 15+6 weeks of gestation) until delivery.
Treatment: OMNi-BiOTiC® METAtox
- ControlNo study treatment, for comparison
Women with a preconceptional BMI ≥25 kg/m2 receiving standard prenatal care without probiotic supplementation.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- To Assess the Possible Influence of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy - a Pilot Study
- Record updated
- 6 November 2026